T8949

Sigma-Aldrich

Telmisartan

≥98% (HPLC), solid

Synonym(s):
BIBR 277, 4′[(1,4′-Dimethyl-2′-propyl[2,6′-bi-1H-benzimidazol]-1′-yl)methyl][1,1′-biphenyl]-2-carboxylic acid
Empirical Formula (Hill Notation):
C33H30N4O2
CAS Number:
Molecular Weight:
514.62
MDL number:
PubChem Substance ID:

Quality Level

assay

≥98% (HPLC)

form

solid

color

white

solubility

DMSO: >5 mg/mL at 60 °C
H2O: insoluble

originator

Boehringer Ingelheim

SMILES string

CCCc1nc2c(C)cc(cc2n1Cc3ccc(cc3)-c4ccccc4C(O)=O)-c5nc6ccccc6n5C

InChI

1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)

InChI key

RMMXLENWKUUMAY-UHFFFAOYSA-N

Gene Information

human ... AGTR1(185)

Looking for similar products? Visit Product Comparison Guide

Application

Telmisartan has been used as an AT1 receptor antagonist to study its effects on mouse models of myocardial infarction. This study reported that telmisartan inhibited the CCN1 upregulation and reduced CCN2 levels atrial cardiomyocytes. Telmisartan has also been used to evaluate its effect on the expression of CCN1 in kidney cortex of mice subjected to myocardial infarction. Furthermore, telmisartan has been used to test its efficacy against tumor growth in mouse models of colorectal cancer.

Packaging

10, 50 mg in glass bottle

Biochem/physiol Actions

Telmisartan is a non-peptide AT1 angiotensin receptor antagonist.

Preparation Note

Telmisartan is soluble in DMSO at a concentration that is greater than 5 mg/ml. It is insoluble in water.

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

RIDADR

NONH for all modes of transport

WGK Germany

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
Tomasz Andrzej Bonda et al.
Folia histochemica et cytobiologica, 51(1), 84-91 (2013-05-22)
Chronic heart failure often leads to worsening of the renal function. Mediators of this process include inflammatory and neuroendocrine factors. CCN1 (Cyr 61), a member of growth factor-inducible immediate early genes, which modulates inflammation and fibrogenesis, is excreted with urine...
M Sharpe et al.
Drugs, 61(10), 1501-1529 (2001-09-18)
Telmisartan is an angiotensin II receptor antagonist that is highly selective for type 1 angiotensin II receptors. It was significantly more effective than placebo in large (n >100), double-blind, randomised, multicentre clinical trials in patients with mild to moderate hypertension....
Marc P Maillard et al.
The Journal of pharmacology and experimental therapeutics, 302(3), 1089-1095 (2002-08-17)
In vitro studies have shown that telmisartan is an insurmountable angiotensin II subtype-1 (AT1) receptor antagonist. Herein, the molecular basis of this insurmountable antagonism has been investigated in vitro, and the effect of telmisartan has been compared in vivo with...
Tomasz A Bonda et al.
Folia histochemica et cytobiologica, 50(1), 99-103 (2012-04-26)
Previous studies have reported the upregulation of CCN proteins early after acute heart injury. The aim of the present work was to evaluate the expression of the CCN1 and CCN2 proteins and their regulation by angiotensin II in the atrial...
Li Li et al.
Diabetes, 62(3), 762-774 (2012-12-15)
The mechanisms of the improvement of glucose homeostasis through angiotensin receptor blockers are not fully elucidated in hypertensive patients. We investigated the effects of telmisartan on insulin signaling and glucose uptake in cultured myotubes and skeletal muscle from wild-type and...
Related Content
Discover Bioactive Small Molecules for ADME/Tox
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.